Titre
Experience with angiotensin II antagonists in hypertensive patients.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Clinical and experimental pharmacology & physiology. Supplement
Auteur(s)
Waeber, B.
Auteure/Auteur
Burnier, M.
Auteure/Auteur
Nussberger, J.
Auteure/Auteur
Brunner, H.R.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0143-9294
Statut éditorial
Publié
Date de publication
1996
Volume
3
Première page
S142
Dernière page/numéro d’article
6
Langue
anglais
Notes
Publication types: Congresses ; Review - Publication Status: ppublish
Résumé
1. The availability of orally active specific angiotensin receptor antagonists (AT1 antagonists) has opened new therapeutic choices and provided probes to test the specific role of the renin-angiotensin system in the pathogenesis of cardiovascular disease. 2. The data available so far suggest that the antihypertensive efficacy of angiotensin receptor antagonists is comparable to that of angiotensin-converting enzyme (ACE) inhibitors. This provides further evidence that this latter class of drugs exerts its effect mainly through blockade of the renin-angiotensin enzymatic cascade. As expected, the association of a diuretic exerts an equally strong additive effect to the antihypertensive efficacy of both classes of drugs. 3. The most common side effect of ACE inhibitors, dry cough, does not occur with AT1 antagonists, which confirms the long-held view that this untoward effect of the ACE inhibitors is due to renin-angiotensin-independent mechanisms. 4. Long-term studies with morbidity/mortality outcome results are needed, before a definite position can be assigned to this newcomer in the orchestra of modern antihypertensive drugs. Notwithstanding, this new class of agents already represents an exciting new addition to our therapeutic armamentarium.
PID Serval
serval:BIB_CE4479240949
PMID
Date de création
2008-03-05T15:40:00.390Z
Date de création dans IRIS
2025-05-21T03:38:24Z